Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma

Casitas B-lineage lymphoma b (Cbl-b) is a ubiquitin-protein ligase and a signal transducing adaptor protein involved in immune regulation, and it may be involved in the development and progression of cancer. We investigated the association between Cbl-b expression and prognosis in patients with resectable pancreatic ductal adenocarcinoma (PDAC). The clinicopathological characteristics and survival data of 134 patients with surgery for PDAC between January 2009 and February 2012 were retrospectively evaluated, and Cbl-b expression was assayed by immunohistochemical staining. The association of Cbl-b expression with clinicopathological features and postoperative prognosis was analyzed. Cbl-b expression was strongly associated with the pathological primary tumor (pT) category (P = 0.005) and pathological TNM (pTNM) stage (P = 0.035), but not with other clinicopathological characteristics (all P > 0.05). In addition to current markers including pathological regional lymph nodes (pN) category, CA19-9, and histological differentiation, univariate and multivariate analysis found that Cbl-b was independently associated with overall survival (OS) of patients with resectable PDAC. Cbl-b was predictive of OS in a subgroup of patients with serum CA19-9 ≥ 37 U/mL. Cbl-b expression combined with pN, histological differentiation, and CA19-9 level could be used as a novel clinical model predictive of OS for patients with resectable PDAC. In conclusion, Cbl-b in resectable PDAC was an independent predictor of adverse prognosis. Cbl-b expression together with pN, histological differentiation, and CA19-9 level might lead to improved risk stratification and prognosis for patients with resectable PDAC.

[1]  F. Jiao,et al.  Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer , 2016, Oncotarget.

[2]  Valérie Taly,et al.  Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker , 2016, Clinical Cancer Research.

[3]  M. Barda-Saad,et al.  Cbl ubiquitin ligases mediate the inhibition of natural killer cell activity , 2016, Communicative & integrative biology.

[4]  Ce Li,et al.  MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells , 2016, Oncotarget.

[5]  N. Hiraoka,et al.  Clinical significance of tumor‐infiltrating immune cells focusing on BTLA and Cbl‐b in patients with gallbladder cancer , 2015, Cancer science.

[6]  Yanju Ma,et al.  The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis , 2015, Oncotarget.

[7]  M. Büchler,et al.  Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. , 2015, Annals of surgery.

[8]  D. Wolf,et al.  Modulation of Immune Cell Functions by the E3 Ligase Cbl-b , 2015, Front. Oncol..

[9]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[10]  Yanju Ma,et al.  Cbl-b inhibits P-gp transporter function by preventing its translocation into caveolae in multiple drug-resistant gastric and breast cancers , 2015, Oncotarget.

[11]  Ke Ma,et al.  Molecular Pathways: Cbl Proteins in Tumorigenesis and Antitumor Immunity—Opportunities for Cancer Treatment , 2014, Clinical Cancer Research.

[12]  Yunpeng Liu,et al.  Serum calcium level used as a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma. , 2014, Clinics and research in hepatology and gastroenterology.

[13]  Yunpeng Liu,et al.  Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study , 2014, World Journal of Surgical Oncology.

[14]  W. Langdon,et al.  E3 ubiquitin ligase Cbl-b in innate and adaptive immunity , 2014, Cell cycle.

[15]  A. Ullrich,et al.  The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells , 2014, Nature.

[16]  Yanju Ma,et al.  Cbl-b Enhances Sensitivity to 5-Fluorouracil via EGFR- and Mitochondria-Mediated Pathways in Gastric Cancer Cells , 2013, International journal of molecular sciences.

[17]  Ying Zheng,et al.  The Incidence and Survival Rate of Population-Based Pancreatic Cancer Patients: Shanghai Cancer Registry 2004–2009 , 2013, PloS one.

[18]  J. Werner,et al.  CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy , 2013, Annals of Surgical Oncology.

[19]  Sungman Park,et al.  CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-β signaling , 2012, Oncogene.

[20]  H. Furukawa,et al.  Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma , 2012, Journal of Gastrointestinal Surgery.

[21]  M. McDevitt,et al.  Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Eeles,et al.  TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer , 2008, British Journal of Cancer.

[23]  A. Siriwardena,et al.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  Michael A. Choti,et al.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience , 2006, Journal of Gastrointestinal Surgery.

[25]  W. Langdon,et al.  c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. , 2005, The Biochemical journal.

[26]  F. Alt,et al.  Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. , 2000, Immunity.

[27]  M. Nau,et al.  cbl-b inhibits epidermal growth factor receptor signaling , 1999, Oncogene.

[28]  A. Basu,et al.  New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. , 2009, The Lancet. Oncology.